Format

Send to

Choose Destination
Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):1-18. doi: 10.1097/PAI.0000000000000163.

Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee.

Author information

1
*Department of Laboratory Hematology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON **Vancouver Costal Health ††Vancouver General Hospital/University of British Columbia, Vancouver, BC ##Department of Pathology, University of Calgary, Calgary, AB, Canada †Canadian Immunohistochemistry Quality Control (CIQC), Vancouver, BC, Canada ‡Institute of Pathology, Aalborg University Hospital, Denmark §Nordic Immunohistochemistry Quality Control (NordiQC), Aalborg, Denmark ∥Griffith University School of Medicine, Gold Coast Campus ¶Australian Institute for Bioengineering and Nano-Technology, University of Queensland, Qld, Australia #Convenor Immunohistochemistry, Anatomical Pathology Program, RCPA QAP Pty Ltd., Sydney, Australia ‡‡Beth Israel Deaconess Medical Center §§Brigham and Women's Hospital, Harvard medical School, Boston, MA ∥∥UK National External Quality Assessment Scheme (UK NEQAS), University College London, London, UK ¶¶University of Washington, Seattle, WA ***Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China †††Chinese Committee for Pathology-Immunohistochemistry Quality Control (CCP-IHCQC) ‡‡‡Keck School of Medicine, University of Southern California, Los Angeles, CA.

Abstract

Diagnostic immunohistochemistry (dIHC) has been practiced for several decades, with an ongoing expansion of applications for diagnostic use, and more recently for detection of prognostic and predictive biomarkers. However, standardization of practice has yet to be achieved, despite significant advances in methodology. An Ad Hoc Expert Committee was formed to address the standardization of controls, which is a missing link in demonstrating and assuring standardization of the various components of dIHC. This committee has also developed a concept of immunohistochemistry critical assay performance controls that are intended to facilitate methodology transfer and harmonization in dIHC. Furthermore, the committee has clarified definitions of IHC assay sensitivity and specificity, with special emphasis on how these definitions apply to positive controls. Recommendations for "best laboratory practice" regarding positive controls for dIHC are specified. The first set of immunohistochemistry critical assay performance controls for several frequently used IHC stains or tests is also developed and presented.

PMID:
25474126
DOI:
10.1097/PAI.0000000000000163
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center